BioNTech Pfizer bispecifics; FDA Pazdur restructure
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- BioNTech and Pfizer presented new bispecific antibody data at the ASCO annual meeting.
- Rick Pazdur of the FDA said the agency sees a “silver lining” amid recent pressures, hinting at a chance to restructure.
- STAT+ says the FDA’s challenges, including competition from China, give the agency a chance to restructure.
Why it matters: Biotech firms and investors watch the bispecifics data for market impact, while FDA’s restructuring will affect approval timelines and pricing for new cancer therapies worldwide.
Ask SkimNews
